GeoVax Labs (GOVX) Expected to Post Quarterly Earnings on Monday

GeoVax Labs (NASDAQ:GOVX) will likely be releasing its Q2 2026 results after the market closes on Monday, July 27th. Analysts expect GeoVax Labs to post earnings of ($2.16) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, July 27, 2026 at 4:30 PM ET.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Thursday, May 14th. The company reported ($2.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.84) by $1.22. On average, analysts expect GeoVax Labs to post $-9 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

GeoVax Labs Stock Performance

Shares of NASDAQ:GOVX opened at $0.73 on Friday. The firm has a market capitalization of $2.54 million, a P/E ratio of -0.04 and a beta of 3.68. The stock has a 50 day moving average price of $1.55 and a 200-day moving average price of $1.86. GeoVax Labs has a 52-week low of $0.69 and a 52-week high of $20.64.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new stake in GeoVax Labs during the 1st quarter valued at about $27,000. HRT Financial LP purchased a new position in GeoVax Labs in the fourth quarter worth about $31,000. Armistice Capital LLC bought a new position in shares of GeoVax Labs in the third quarter worth approximately $253,000. Finally, Renaissance Technologies LLC bought a new position in shares of GeoVax Labs in the fourth quarter worth approximately $104,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on GOVX. Wall Street Zen upgraded GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a report on Friday, July 17th. Finally, D. Boral Capital reiterated a “hold” rating on shares of GeoVax Labs in a research note on Thursday, April 16th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce” and an average price target of $150.00.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.